DOCSLIB.ORG

02-09-2017 06:01:33Pm Esmo.Org Type

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
02-09-2017 06:01:33Pm Esmo.Org Type 08-09-2017 10:00 - 11:30 Type: Special Session Palma Title: Medical oncology as a contributor to global policy: How to improve national cancer Auditorium plans Chair(s): G. Curigliano, IT; L. Stevens, US 10:00 - 10:05 Introduction L. Stevens, Rio De Janeiro, BR 10:05 - 10:20 Overview of NCCP, including forming the multi-disciplinary and multi-sectoral partnership A. Ilbawi, Geneva, CH 10:20 - 10:35 Example from Central Asia Leadership Forum D. Kaidarova, Almaty, KZ 10:35 - 10:50 Example from Central Europe J. Jassem, Gdańsk, PL 10:50 - 11:05 Example from Eastern Europe S. Krasny, Minsk, BY 11:05 - 11:30 Interactive Q&A G. Curigliano, Milan, IT Last update: 02-09-2017 06:01:33pm esmo.org 12:00 - 13:30 Type: Opening session Madrid Auditorium Title: Opening session and Award lectures Chair(s): F. Ciardiello, IT 12:00 - 12:10 ESMO Presidential Address F. Ciardiello, Naples, IT 12:10 - 12:15 EACR Presidential Address A. Berns, Amsterdam, NL 12:15 - 12:20 Welcome to Madrid M. Martin Jimenez, Madrid, ES 12:20 - 12:25 ESMO 2017 Scientific Address A. Sobrero, Genova, IT 12:25 - 12:30 EACR 2017 Scientific Address R. Marais, Manchester, GB 12:30 - 12:32 Presentation of the ESMO Award by C. Zielinski, Vienna, AT 12:32 - 12:47 ESMO Award lecture - Oncology: The importance of teamwork M. Martin Jimenez, Madrid, ES 12:47 - 12:49 Presentation of the ESMO Translational Research Award by C. Zielinski, Vienna, AT 12:49 - 13:04 ESMO Translational Research Award lecture: Monitoring and targeting colorectal cancer evolution A. Bardelli, Candiolo, (TO)/IT 13:04 - 13:06 Presentation of the ESMO Lifetime Achievement Award by C. Zielinski, Vienna, AT 13:06 - 13:21 ESMO Lifetime Achievement Award lecture J. Baselga, New York, NY/US 13:21 - 13:21 Close and Welcome refreshments in the exhibition 14:00 - 15:30 Type: Proffered Paper session Barcelona Auditorium Title: Gastrointestinal tumours, non-colorectal 1 Chair(s): E. Van Cutsem, BE; Y.-K. Kang, KR Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 14:12 LBA27_PR - Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO) 1 2 3 4 5 6 7 S.-E. Al-Batran , C. Pauligk , N. Homann , H. Schmalenberg , H.-G. Kopp , G.M. Haag , K. Luley , G. 4 8 9 2 10 11 12 Folprecht , S. Probst , P. Thuss-Patience , J. Trojan , M. Koenigsmann , U. Lindig , M. Pohl , S. 13 14 1 13 1 15 1 Kasper , M. Möhler , T. Goetze , M. Schuler , E. Jaeger , R.D. Hofheinz ; Frankfurt Am Main, 2 3 4 5 6 7 DE, Frankfurt, DE, Wolfsburg, DE, Dresden, DE, Tübingen, DE, Heidelberg, DE, Lübeck, 8 9 10 11 12 13 Schleswig-Holstein/DE, Bielefeld, DE, Berlin, DE, Hannover, DE, Jena, DE, Bochum, DE, 14 15 Essen, DE, Mainz, DE, Mannheim, DE 14:12 - 14:24 615O_PR - Hybrid Minimally Invasive vs. Open Esophagectomy for patients with Esophageal Cancer: Long-term outcomes of a multicenter, open-label, randomized phase III controlled trial, the MIRO trial 1 2 3 4 5 6 7 C. Mariette , S. Markar , T.S. Dabakuyo-Yonli , B. Meunier , D. Pezet , D. Collet , X. D'journo , C. 8 9 10 11 12 1 2 Brigand , T. Perniceni , N. Carrere , F. Bonnetain , G. Piessen ; Lille, CEDEX/FR, London, GB, 3 4 5 6 7 8 9 Dijon, FR, Rennes, FR, Clermont Ferrand, FR, Bordeaux, FR, Marseille, FR, Strasbourg, FR, 10 11 12 Paris, FR, Toulouse, FR, Besançon, CEDEX/FR, Lille, FR 14:24 - 14:39 Invited Discussant LBA27_PR and 615O_PR A. Roth, Geneva, CH 14:39 - 14:51 616O - Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB) 1 2 3 4 5 6 6 7 6 J. Tabernero , P. Hoff , L. Shen , A. Ohtsu , M. Shah , K. Cheng , C. Song , H. Wu , J. Eng-Wong , 8 1 2 3 4 5 6 Y.-K. Kang ; Barcelona, ES, Sao Paulo, BR, Beijing, CN, Kashiwa, Chiba/JP, New York, NY/US, 7 8 San Francisco, US, Shanghai, CN, Seoul, Songpa-gu/KR 14:51 - 15:03 617O - A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) 1 2 3 4 5 6 7 8 N. Boku , Y.-K. Kang , T. Satoh , Y. Chao , K. Kato , H.C. Chung , J.-S. Chen , K. Muro , W.K. Kang 6 9 6 10 11 12 1 2 , T. Yoshikawa , S.C. Oh , T. Tamura , K.-W. Lee , L.-T. Chen ; Kawasaki, Kanagawa/JP, 3 4 5 6 7 8 Seoul, Songpa-gu/KR, Suita, Osaka/JP, Taipei, TW, Tokyo, JP, Seoul, KR, Taoyuan, TW, 9 10 11 12 Nagoya, Aichi/JP, Yokohama, JP, Osaka, JP, Seongnam, KR, Tainan, TW 15:03 - 15:15 LBA28_PR - KEYNOTE-059 Update: Efficacy and Safety of Pembrolizumab Alone or in Combination With Chemotherapy in Patients With Advanced Gastric or Gastroesophageal (G/GEJ) cancer 1 2 3 4 5 6 7 8 6 Z. Wainberg , S. Jalal , K. Muro , H. Yoon , M. Garrido , T. Golan , T. Doi , D. Catenacci , R. Geva , 9 10 11 12 11 13 13 13 G. Ku , J. Bleeker , Y.-J. Bang , H. Hara , H.C. Chung , M. Savage , J. Wang , M. Koshiji , 14 15 1 2 3 4 R. Dalal , C. Fuchs ; Los Angeles, CA/US, Indianapolis, IN/US, Nagoya, Aichi/JP, Rochester, 5 6 7 8 9 10 MN/US, Santiago, CL, Tel Aviv, IL, Kashiwa, Chiba/JP, Chicago, IL/US, New York, NY/US, 11 12 13 14 15 Sioux Falls, SD/US, Seoul, KR, Saitama, JP, Kenilworth, NJ/US, Rahway, US, New Haven, CT/US 15:15 - 15:30 Invited Discussant 616O, 617O and LBA28 E. Van Cutsem, Leuven, BE Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 15:30 Type: Proffered Paper session Sevilla Auditorium Title: Genitourinary tumours, prostate Chair(s): J. de Bono, GB; S. Gillessen, CH 14:00 - 14:12 LBA31_PR - Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476) 1 2 3 4 5 6 7 6 M. Sydes , M. Mason , M. Spears , N. Clarke , D. Dearnaley , A. Ritchie , M. Russell , C. Gilson , R. 7 6 8 3 9 10 6 11 Jones , J. de Bono , S. Gillessen , R. Millman , S. Tolan , J. Wagstaff , S. Chowdhury , J. Lester , 12 13 14 15 1 2 3 4 D. Sheehan , J. Gale , M. Parmar , N. James ; London, UK/GB, Cardiff, GB, Wcb Nh, GB, M 5 6 7 8 9 10 11 Hd, GB, Sutton, GB, London, GB, Glasgow, GB, St. Gallen, CH, Wirral, GB, Swansea, GB, 12 13 14 15 Wales, GB, Exeter, GB, Portsmouth, GB, London, London/GB, Birmingham, GB 14:12 - 14:24 783O - Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO) 1 2 3 4 5 6 7 K. Chi , A. Protheroe , A. Rodriguez Antolin , G. Facchini , H. Suttmann , N. Matsubara , Z.-Q. Ye , B. 8 9 10 11 12 13 9 14 1 Keam , T. Li , K. McQuarrie , B. Jia , P. De Porre , J. Martin , M. Todd , K. Fizazi ; 2 3 4 5 6 Vancouver, British Columbia/CA, Oxford, GB, Madrid, ES, Napoli, IT, Hamburg, DE, Kashiwa, 7 8 9 10 11 12 Chiba/JP, Wuhan, CN, Seoul, KR, Raritan, NJ/US, Horsham, PA/US, Shanghai, CN, Antwerp, 13 14 BE, Buckinghamshire, GB, Villejuif Cedex, FR 14:24 - 14:36 784O - Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial 1 2 3 4 5 6 7 S. Oudard , I. Latorzeff , A. Caty , L. Miglianico , E. Sevin , A.-C. Hardy Bessard , R. Delva , F. 8 2 9 10 11 12 13 Rolland , C. Chevreau , F. Priou , P. Beuzeboc , G. Gravis , C. Linassier , P. Gomez , E. Voog 14 1 15 16 1 17 1 2 , P. Chinet , X. Muracciole , C. Abraham Jaillon , R. Elaidi , S. Culine ; Paris, FR, Toulouse, 3 4 5 6 7 8 FR, Lille Cedex, FR, St. Grégoire, FR, Caen, FR, Plérin, FR, Angers, FR, Saint-Herblain, 9 10 11 12 CEDEX/FR, La Roche Sur Yon, CEDEX 9/FR, Paris, CEDEX 5/FR, Marseille, CEDEX 9/FR, 13 14 15 16 17 Tours, CEDEX 9/FR, Rouen, FR, Le Mans, FR, Marseille, FR, Le Chesnay, FR, Paris, CEDEX 10/FR 14:36 - 14:51 Invited Discussant LBA31, 783O and 784O C. Sternberg, Roma, IT 14:51 - 15:03 785O - Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA 1 2 2 2 2 2 2 2 M. Hofman , S. Sandhu , P. Eu , J. Price , T. Akhurst , A. Iravani , G. Kong , A. Ravi-Kumar , S. 2 2 2 2 2 2 1 2 Williams , S.-P. Thang , D. Murphy , M. Scalzo , R. Hicks , J. Violet ; Melbourne, AU, Melbourne, VIC/AU 15:03 - 15:15 LBA32 - PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC) Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 1 4 E. Castro Marcos , N.
Load more

Recommended publications
  • RICE, CARL ROSS. Diocletian's “Great
    ABSTRACT RICE, CARL ROSS. Diocletian’s “Great Persecutions”: Minority Religions and the Roman Tetrarchy. (Under the direction of Prof. S. Thomas Parker) In the year 303, the Roman Emperor Diocletian and the other members of the Tetrarchy launched a series of persecutions against Christians that is remembered as the most severe, widespread, and systematic persecution in the Church’s history. Around that time, the Tetrarchy also issued a rescript to the Pronconsul of Africa ordering similar persecutory actions against a religious group known as the Manichaeans. At first glance, the Tetrarchy’s actions appear to be the result of tensions between traditional classical paganism and religious groups that were not part of that system. However, when the status of Jewish populations in the Empire is examined, it becomes apparent that the Tetrarchy only persecuted Christians and Manichaeans. This thesis explores the relationship between the Tetrarchy and each of these three minority groups as it attempts to understand the Tetrarchy’s policies towards minority religions. In doing so, this thesis will discuss the relationship between the Roman state and minority religious groups in the era just before the Empire’s formal conversion to Christianity. It is only around certain moments in the various religions’ relationships with the state that the Tetrarchs order violence. Consequently, I argue that violence towards minority religions was a means by which the Roman state policed boundaries around its conceptions of Roman identity. © Copyright 2016 Carl Ross Rice All Rights Reserved Diocletian’s “Great Persecutions”: Minority Religions and the Roman Tetrarchy by Carl Ross Rice A thesis submitted to the Graduate Faculty of North Carolina State University in partial fulfillment of the requirements for the degree of Master of Arts History Raleigh, North Carolina 2016 APPROVED BY: ______________________________ _______________________________ S.
    [Show full text]
  • Le Manovre Contro La Distensione
    In 3. pagina leggete tllttO SU I VINCITORI IH IEIM M O S S nella Targa Florio ROMA - LAZIO 0-0 MINARDI nel trofeo Matteotti Servìzi di ENNIO PALOCCI DELLUNEDI RENATO VENDUTI ANGLESIO ai mondiali eli spada GIORGIO NIB1 k ORGANO DEL PARTITO COMUNISTA ITALIANO L( ;j4|ete in sesia pnijinu i nostri servizi ANNO XXXII (Nuova Serie) - N. 41 (288) LUNEDI' 17 OTTOBRE 1955 Una copia L. 25 - Arretrata L. 30 A POCHI GIORNI DALL'INIZIO DELLA CONFERENZA DI GINEVRA Kneerenko a Roma Il xiie presiitentr drl (011- SÌRIÌO ilell'l'KSS «ara ritr- I capi clericali intensificano xuto oirsi ilall'on. Srcui Il vice-presidente A e '. Con-ig'.io dei ministri <ie.- i'URSS. V Va di 111 ir Kuceven- [10. è giunto tè'"' se";i alle 17.30 ;i!!'ae:opor".o di Ciam- le manovre contro la distensione pino proveniente da Pavt- g., accompagnato da una delcga/.ione <ii esperti nel Longo sottolinea a Bari l'interesse dell'Italia di migliorare i rapporti con l'URSS e la Cina popolare - Pajettacamp o della edilizia, per compiere una vi.-ita ili qual­ a Milano afferma che uno distensione all'interno del Paese presuppone il rispetto dei diritti dei lavoratori che giorno a Roma e in ai- ire citta italiane. Il vice-presidente del A dicci giurili d.iil'uii/10 tifi­ Milli) di musi 1.1U- del tulio III.I- da della apertura n .-ini Consiglio. Kneerenko. che la ter^a Luuteriii/.i <h (une- • latti- a risiilx e e quelli che Il discorso di Longo stia, la strada cioè, verso un Pajetta parla a Milano 1.1 compiuto una analoga \ra, alln quale p.uU-ctpciaiuio li 1 i ilerni prolileini d'ita- profondo rinnovamento poli­ xi- ".a ai Francia, compierà i inìui^tri dcijli l.vlin ililk- ll.l.
    [Show full text]
  • Impression De La Page Entière
    Remerciements Cette thèse a été pour moi une période très enrichissante tant scientifiquement que humainement. Je souhaite remercier toutes les personnes qui y ont contribué de près ou de loin, et qui ont permis de rendre ces trois années aussi riches que ce qu’elles ont été. Je souhaite tout d’abord remercier le Dr. Azzedine Bousseksou de m’avoir accueillie au sein de son établissement. Je remercie également tous les membres de mon jury pour avoir évalué mon travail : Dr. Catherine Belle et Dr. Yves Le Mest, merci d’avoir accepté d’être rapporteurs de ma thèse, Dr. Eric Benoist, Dr. Katell Sénéchal-David, et Dr. Stéphane Torelli, merci d’avoir accepté d’être examinateurs de ma thèse. Je souhaite maintenant remercier la personne sans qui tout cela n’aurait pas été possible : Christelle. Merci pour ta confiance, merci pour ta patience, merci d’avoir cru en moi !!! Tu m’as transmis tellement de choses… Tu es un puits de connaissances et d’idées inépuisable ! Tu m’as permis de faire ce que j’avais envie, de tester, d’expérimenter, etc. même si parfois j’aurais pu m’abstenir… Tu m’as également laissé faire des enseignements, tu m’as fait découvrir le monde des congrès, j’ai pu avoir des stagiaires, j’ai pu aller en Argentine en collaboration, etc. (la liste est tellement longue que je vais m’arrêter là !) Je ne te remercierai jamais assez pour tout ça ! Cette thèse a été pour moi un super moment de ma vie (j’espère que pour toi, ça n’a pas été un trop long calvaire ;) ) Il ne me reste plus qu’une chose à espérer…que tu tiennes ta promesse le 1er décembre… Peter, un grand merci à toi d’être venu me proposer de joindre ton équipe.
    [Show full text]
  • Elettorato Definitivo Del 07/07/2011<Br>Ricercatori
    Ministero dell Istruzione,, dell ,Università e della Ricerca II sessione 2010 Elettorato Definitivo del 07/07/2011 Ricercatori 1 Elettorato Definitivo Settore: AGR/01 - Economia ed estimo rurale Bandi previsti:6 Numero di docenti necessari alla costituzione della lista dei sorteggiabili: 36 Elettorato attivo N° Cognome Nome Ateneo Facoltà Settore Nota ** Data di nascita Data di nomina 1 AMATA Francesco Univ. CATANIA AGRARIA AGR/01 30/07/1944 01/03/2006 2 ANTONELLI Gervasio Univ. URBINO ECONOMIA AGR/01 24/03/1946 01/11/1999 3 BANTERLE Alessandro Univ. MILANO AGRARIA AGR/01 STR. 05/07/1960 01/11/2010 4 BASILE Elisabetta ROMA "La Sapienza" ECONOMIA (*) AGR/01 01/08/1951 01/11/2001 5 BEGALLI Diego Univ. VERONA ECONOMIA AGR/01 23/09/1957 01/03/2000 6 BERNETTI Iacopo Univ. FIRENZE AGRARIA AGR/01 27/01/1963 01/11/2000 7 BERTAZZOLI Aldo Univ. BOLOGNA AGRARIA AGR/01 19/07/1959 01/11/2001 8 BOATTO Vasco Ladislao Univ. PADOVA AGRARIA AGR/01 27/06/1950 30/10/1986 9 BOVE Ettore Univ. BASILICATA ECONOMIA AGR/01 11/04/1947 01/11/1994 10 BRUNORI Gianluca Univ. PISA AGRARIA AGR/01 25/03/1960 30/12/2004 11 CANNATA Giovanni Univ. MOLISE ECONOMIA AGR/01 CUN 08/03/1947 01/11/1991 12 CARRA' Giuseppina Univ. CATANIA AGRARIA AGR/01 14/08/1951 01/11/1994 13 CASATI Dario Univ. MILANO AGRARIA AGR/01 18/09/1943 01/11/1980 14 CASINI Leonardo Univ. FIRENZE AGRARIA AGR/01 19/06/1958 01/11/1994 15 CECCHI Claudio ROMA "La Sapienza" ECONOMIA (*) AGR/01 29/09/1949 01/11/2000 16 CESARETTI Gian Paolo "Parthenope" NAPOLI ECONOMIA AGR/01 19/11/1943 22/04/1986 17 CHANG Ting Fa Margherita Univ.
    [Show full text]
  • UCSF UC San Francisco Electronic Theses and Dissertations
    UCSF UC San Francisco Electronic Theses and Dissertations Title Dynamic Tuning of CD4+ T cells by Tonic Signals Permalink https://escholarship.org/uc/item/6r11z6ft Author Myers, Darienne Ross Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Dynamic Tuning of CD4+ T cells by Tonic Signals by Darienne Myers DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHiLOSOPFTY in Biomedical Sciences in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Copyright 2017 by Darienne R. Myers ii DEDICATION AND ACKNOWLEDGEMENTS Chapter 1 of this dissertation is a reprint of material published in Myers, D.R., Roose, J.P., 2016. Kinase and Phosphatase Pathways in T Cells. Ratcliffe, M.J.H. (Editor in Chief), Encyclopedia of Immunobiology, Vol. 3, pp. 25-37. Oxford: Academic Press. Chapter 6 is a reprint of Daley et al, Rasgrp1 mutation increases naïve T-cell CD44 expression and drives mTOR-dependent accumulation of Helios+ T cells and autoantibodies. eLIFE 2013; 2:e01020. The research presented in this dissertation is the result of hard work, and it could not have been done without the support of many people. First, I would like to thank my mentor, Jeroen Roose. Jeroen, thank you for everything. You have taught me so much about being a scientist: how to think critically and strategically about experimental design and analysis, how to write, how to give clear and interesting presentations, and how to share my knowledge with my own mentees. I appreciate how you set me up with three fascinating projects and gave me the freedom to explore the questions I found most interesting, always providing me with guidance when I needed it.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Olmsted Syndrome: Clinical, Molecular and Therapeutic Aspects Sabine Duchatelet1,2 and Alain Hovnanian1,2,3*
    Duchatelet and Hovnanian Orphanet Journal of Rare Diseases (2015) 10:33 DOI 10.1186/s13023-015-0246-5 REVIEW Open Access Olmsted syndrome: clinical, molecular and therapeutic aspects Sabine Duchatelet1,2 and Alain Hovnanian1,2,3* Abstract Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques, but which shows considerable clinical heterogeneity. The disease starts usually at birth or in early childhood. About 73 cases have been reported worldwide. OS is observed in both sexes, although male cases are more frequent. The most suggestive symptoms associate PPK with pseudoainhum and periorificial keratotic plaques. Frequently associated features include hair and nail abnormalities, leukokeratosis, corneal default and recurrent infections. Pain and itching are variable but can be severe. Most of reported OS cases are sporadic, although familial cases with different mode of inheritance were also described. Mutations in TRPV3 (Transient receptor potential vanilloid-3) gene have recently been identified as a cause of autosomal dominant (gain-of-function mutations) or recessive OS. Mutations in MBTPS2 (membrane-bound transcription factor protease, site 2) gene were identified in a recessive X-linked form. The diagnosis relies mainly on clinical features associating severe PPK and periorificial keratotic plaques, but can be challenging in patients with incomplete phenotype or atypical features. OS has to be differentiated from other severe forms of PPK including Vohwinkel, Clouston, Papillon-Lefèvre or Haim-Munk syndromes, Mal de Meleda, pachyonychia congenita, Tyrosinemia type II and acrodermatitis enteropathica. When differential diagnoses are difficult to exclude, genetic studies are essential to search for a TRPV3 or MBTPS2 mutation.
    [Show full text]
  • Onorificenze Concesse Anno 2007
    N.B. - A fianco di ciascun nominativo sono indicati luogo e data di nascita PRESIDENZA DEL CONSIGLIO DEI MINISTRI STRANIERI (ART. 7) Indirizzo Con decreti in data 5 febbraio 2007 Visita Ufficiale del Signor Presidente della Repubblica a Sua Santità Benedetto XVI Cavaliere di Gran Croce Dalla Torre del Tempio di Prof. Giuseppe Roma 27/08/1943 Sanguinetto Lombardi Rev.mo P. Federico Saluzzo 29/08/1942 Mamberti S.E. Rev.ma Dominique Marrakech 07/03/1952 Mons. Grande Ufficiale Giani Dott. Domenico Arezzo 16/08/1962 Mäder Col. Elmar Th. Heneau 28/07/1963 Commendatore Conversi Dott. Paolo Roma 31/08/1971 D'Ercole Rev.Don Giovanni Morino 05/10/1947 Di Cerbo Mons. Valentino Frasso Telesino 16/09/1943 Di Giovanni Dott.ssa Francesca Palermo 24/03/1953 Duthel Mons. François Rozier en Donzy 14/07/1951 Gloder Mons. Giampiero Asiago 15/05/1958 Martignani Rev. P. Luigi Borgo Tossignano 17/07/1955 Piechota Rev.Don Lech Lubin 28/07/1962 Rajic Mons. Petar Toronto 12/06/1959 Rampin Mons. Gianpietro Vespolate 29/09/1949 Rudelli Mons. Paolo Gazzaniga 16/07/1970 Scotti Mons. Assunto Cologno Al Serio 05/03/1955 Thevenin Mons. Nicolas Saint-Dizier 05/06/1958 Trevisan Sig. Bruno Campodoro 28/11/1941 Wells Mons. Peter Brian Tulsa 12/05/1963 Xuereb Mons. Alfred Malta 14/10/1958 Cavaliere Cestiè Sig. Cristian Roma 25/08/1973 Coracci Sig. Ciro Roma 21/04/1974 Di Pietro Sig. Carmine Crognaleto 22/03/1945 D'Incoronato Sig. Benedetto Castelvecchio Calvisio 09/07/1950 Enea Sig. Antonino Messina 18/07/1958 Filippi Sig.
    [Show full text]
  • Author Index
    Author Index Abdennadher, Slim 411 De Gloria, Alessandro 228, 375, 385 Alem, Leila 121 de Jong, Ton 401 Ambra, Pesenti 292 de Leao, Alvaro Gehlen 368 Aminoff, Anna 560 de Smale, Stephanie 506 Antikainen, Maria 560 Demirtzis, Elias 385 Antoniou, Angeliki 218 Dignum, Frank 100 Apostolakis, Konstantinos C. 80 Dimaraki, Evaggelia 80 Arnab, Sylvester 452 Dimitropoulos, Kosmas 80 Arnedo-Moreno, Joan 530 dos Santos, Alysson Diniz 111 Augello, Agnese 100 Drees, Sebastian 23 Avveduto, Giovanni 121 Dufva, Mikko 560 Duncan, Michael 452 Baalsrud-Hauge, Jannicke 228, 393, 550 Duqueroie, Bertrand 393 Baek, Seungho 181 Bampatzia, Stavroula 218 Ecrepont, Adrien 312 Bandini, Stefania 361 Elen, Jan 401 Barabino, Giulio 385 Barrios, Yeray 336 Fijnheer, Jan Dirk 12 Bauer, René 323 Floryan, Mark 161 Becker, Jana 540 Fogli, Daniela 329 Behrens, Sadie 71 Frank, Erik 151 Bellotti, Francesco 228, 375, 385 Fraternali, Piero 111 Bendl, Harald 42 Freese, Maria 23 Bergamasco, Massimo 121 Berta, Riccardo 228, 375, 385 Gadia, Davide 348 Bond, David 441 Gamberini, Luciano 292 Bonnechère, Bruno 302 Gentile, Manuel 100 Bremond, François 286 Georgiadis, Konstantinos 517 Brondi, Raffaello 121 Ger, Pablo Moreno 32 Girard, Benoit 312 Cabitza, Federico 329 Göbl, Barbara 266 Campion, Simon 494 González, Carina S. 336, 530 Cardullo, Stefano 292 Götz, Ulrich 323 Carrozzino, Marcello 121 Grubert, Simon 71 Costa, Joao 421 Cucari, Giovanni 208 Haidon, Corentin 312 Curatelli, Francesco 245, 385 Hamed, Injy 411 Han, JungHyun 181 da Silva, Flávio S. Correa 361 Hansen, Poul Kyvsgaard
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • HMRVBMIS MOIORLESS SERVEL Truman Against Bombing Manchuria
    'VV' :fllanrl;r0tpr lEttpnfn^ 1|?ralh WEDNESDAY. APRIL 11. 1961 Join With Your Neighbors—7 Save Rags for Cancer Thee." Ronald Borkus rendered a ter'a wife to the annual MinlateFa Mrs. John Teomans served tea Sunday were Mr. and Mra. B. G. The taiga la one of the greatest to 2,000 miles wide, scrota Si­ vocal aolo aa the special musical Wivea Conference to be held thia and aandwlches. Nelson and Miss Ellen Edstrom of forest areas of the world—8ome beria and consisting principally of | ATorago Daily Net Press Run TheWooUifOr lilB lil Reports Audover selection, year at tha Monteweae House, New Supper, guesU at the home of Hartford and Mr: and Mrs. George 4,000 miles long and from 1,000 coniferous trees. For the Week Ending ToUand County Fans Bureau Haven in June. Mr. and Mrs. Howard Spear on NelMn. A pril 7, 1081 Fereeaal at 0. & Weather Bmess Revenue Boost H m annual msetlng of the And­ will sponsor a Garden meetlAg at Action waa taken on the formal over Congregational church wrlll North Coventry Grange hall on ballot of the Hartford District, be held In the Social room on A pril 13 at 8 p. m. There will be Feltowahlp Congregational Chris­ 10,168 TPsOw elteidy. rilpwesa la the tian Women. THURSDAY im alU'ilFiiiirir IwUFullUt ItlF raill afternoon: tonight rain; Friday , , Haw n m a. ApiH ll^IncwM e April 30 at 8 p.m. movies, garden Ideas and plans, Member of the Andit Officers of the church and church Voted to pay our dues to the speakers, questions and answers and Bareaa of CUrcnlatlone of M on *»««« 16,000,000 bi opent- organizations are requested to hand and a quiz with prizes.
    [Show full text]